Want to see ABBV full AI Analyst Report?
ABBV Stock Chart & Stats
$265.79
$1.69(0.65%)
At close: 4:00 PM EDT
$265.79
$1.69(0.65%)
Day’s Range― - ―
52-Week Range$190.75 - $267.47
Previous CloseN/A
Volume289.56K
Average Volume (3M)4.90M
Market Cap
$453.19B
Enterprise Value$509.95K
Total Cash (Recent Filing)$6.57B
Total Debt (Recent Filing)$70.82B
Price to Earnings (P/E)72.2
Beta0.07
Next Earnings
Oct 23, 2026EPS Estimate
3.86Next Dividend Ex-DateN/A
Dividend Yield2.66%
Share Statistics
EPS (TTM)3.55
Shares Outstanding1,767,117,300
10 Day Avg. Volume3,876,946
30 Day Avg. Volume4,898,986
Financial Highlights & Ratios
PEG Ratio-77.13
Price to Book (P/B)-123.96
Price to Sales (P/S)6.63
P/FCF Ratio22.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$280.10Price Target Upside5.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
EPS Forecast (FY)14.03
Revenue Forecast (FY)$67.61B
Bulls Say, Bears Say
Bulls Say
Immunology GrowthRapid growth in SKYRIZI and RINVOQ is shifting AbbVie toward newer immunology franchises with continued market-share gains expected. This supports durable revenue expansion and helps offset erosion from older products over the next several quarters.
Pipeline ExpansionThe completed Apogee acquisition broadens AbbVie’s immunology pipeline across large inflammatory indications and adds late- and early-stage assets. Its development capabilities and potential for durable dosing could strengthen long-term franchise depth beyond current growth brands.
Cash Generation And MarginsStrong operating and free cash flow, together with very high gross margins, indicates substantial internal funding capacity for research, business development and debt service. Free cash flow closely matching earnings also supports the quality and durability of reported profitability.
Bears Say
High LeverageHeavy debt and negative equity make AbbVie’s capital structure less resilient and reduce flexibility during operating setbacks. Financing costs can absorb more cash, while the company may need multiple years of cash generation to materially improve debt coverage.
Legacy Product ErosionSharp declines in major legacy products create a continuing revenue headwind and increase dependence on newer franchises to sustain growth. Biosimilar competition, pricing pressure and share loss can persist, making portfolio replacement an ongoing execution requirement.
Acquisition Earnings DragThe Apogee transaction expands the pipeline but imposes several years of expected earnings dilution before projected accretion. Combined with acquired R&D expense and financing needs, this may pressure margins and limit near-term benefits from the strategic investment.
AbbVie News
ABBV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was $190.75 and its highest was $267.47 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is $453.19B.
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Oct 23, 2026 which is in 46 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Jul 31, 2026. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.605 by $0.045.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $1.73 which represents an annual dividend yield of 2.66%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 3.86.
How many shares outstanding does AbbVie have?
AbbVie has 1,767,117,300 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $3.65 in its last earnings report, beating expectations of $3.605. Following the earnings report the stock price went down -2.513%.
Which hedge fund is a major shareholder of AbbVie?
Currently, no hedge funds are holding shares in ABBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$280.10 (5.38% Upside)
$280.10 (5.38% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 83%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.13%
12-Months-Change
Fundamentals
Return on Equity
2.66%
Trailing 12-Months
Asset Growth
-1.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
AbbVie
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
ABBV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum: above‑consensus results, double‑digit growth across key franchises (notably SKYRIZI and RINVOQ), multiple regulatory approvals, raised guidance, and a broadened pipeline via the Apogee deal. These positives are tempered by expected declines in legacy products (HUMIRA, IMBRUVICA), modest softness in some aesthetics lines, acquisition‑related dilution and IPR&D expense, and higher interest costs and FX headwinds. On balance the company presented durable growth drivers and ample financial flexibility despite near‑term dilution and known legacy declines.View all ABBV earnings summariesABBV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
ABBV Stock 12 Month Forecast
Average Price Target
$280.10
▲(5.38% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
20.80% Mutual Funds
14.02% Other Institutional Investors
41.67% Public Companies and Individual Investors